Drugs / Gepaktiv
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07068191 | Jun → Jul 2025 overdue | NAFLD1, alcoholic fatty liver disease | Phenomen Pharma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gepaktiv | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07068191 ↗ |
| Known as | Phenomenon | “Randomized Comparative Clinical Study of the Dietary Supplement "Gepaktiv" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in...” NCT07068191 ↗ |